The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Exclusive agreement covers 13 Central and Eastern European marketsCollaboration will help expand access to VANFLYTA for ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...

Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...

In this retrospective study, researchers stratified pediatric AML patients by risk and aimed to determine whether some could receive fewer chemotherapy cycles without affecting relapse and survival ...

Daiichi Sankyo and GENESIS Pharma will distribute and commercialize quizartinib, brand name VANFLYTA, in 13 markets.

DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

We are thrilled to welcome leaders of Sherwin and Becker’s caliber to the executive team at Galecto,” said Hans Schambye, Ph.D., Chief Executive Officer of Galecto. “Their extensive experience in drug ...

Scientists at Mount Sinai have created an artificial intelligence system that can predict how likely rare genetic mutations are to actually cause disease. By combining machine learning with millions ...

Harry Aikines-Aryeetey has myostatin deficiency Getty Images; design: Kelsea Petersen “A blessing and a curse” is how Harry Aikines-Aryeetey describes the genetic quirk that means his body carries ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...